The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets.

IF 4.9 2区 医学 Q1 PHARMACOLOGY & PHARMACY Expert opinion on investigational drugs Pub Date : 2025-01-01 Epub Date: 2025-02-08 DOI:10.1080/13543784.2025.2462615
Kevin Lam, Gary Peltz, Walter K Kraft
{"title":"The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets.","authors":"Kevin Lam, Gary Peltz, Walter K Kraft","doi":"10.1080/13543784.2025.2462615","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Opioid use disorder and neonatal opioid withdrawal syndrome are persisting consequences of the opioid epidemic in the United States. Current pharmacologic approaches primarily utilize opioid replacement therapy, but non-opioid therapeutics could have advantages. Preclinical and clinical data suggest modulation of the serotonergic system as a novel therapeutic approach in relieving opioid withdrawal syndromes.</p><p><strong>Areas covered: </strong>Serotonin receptors that have been reported to mediate opioid withdrawal signs based on preclinical findings are identified and described. Extant clinical studies assessing the modulation of these receptors on opioid withdrawal outcomes are then summarized.</p><p><strong>Expert opinion: </strong>While medications that serve as agonists or antagonists to serotonin receptor subtypes have the potential for treatment of opioid withdrawal and neonatal opioid withdrawal syndrome, much of the evidence is tenuous. The supportive data are mainly derived from preclinical studies, and the measured clinical efficacy has been variable, but reductions in symptom severity are consistently noted. Serotonergic modulation offers a non-opioid pathway to relieving opioid withdrawal manifestations, which is especially useful for neonates as changes in neuroplasticity have been noted with postnatal opioid use. Potential benefits warrant additional studies to clarify the mechanisms for their effect and for measuring how effective these agents are in human disease.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"49-59"},"PeriodicalIF":4.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11899659/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2025.2462615","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Opioid use disorder and neonatal opioid withdrawal syndrome are persisting consequences of the opioid epidemic in the United States. Current pharmacologic approaches primarily utilize opioid replacement therapy, but non-opioid therapeutics could have advantages. Preclinical and clinical data suggest modulation of the serotonergic system as a novel therapeutic approach in relieving opioid withdrawal syndromes.

Areas covered: Serotonin receptors that have been reported to mediate opioid withdrawal signs based on preclinical findings are identified and described. Extant clinical studies assessing the modulation of these receptors on opioid withdrawal outcomes are then summarized.

Expert opinion: While medications that serve as agonists or antagonists to serotonin receptor subtypes have the potential for treatment of opioid withdrawal and neonatal opioid withdrawal syndrome, much of the evidence is tenuous. The supportive data are mainly derived from preclinical studies, and the measured clinical efficacy has been variable, but reductions in symptom severity are consistently noted. Serotonergic modulation offers a non-opioid pathway to relieving opioid withdrawal manifestations, which is especially useful for neonates as changes in neuroplasticity have been noted with postnatal opioid use. Potential benefits warrant additional studies to clarify the mechanisms for their effect and for measuring how effective these agents are in human disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
导言:阿片类药物使用障碍和新生儿阿片类药物戒断综合征是美国阿片类药物流行的长期后果。目前的药物疗法主要采用阿片类药物替代疗法,但非阿片类药物疗法也有其优势。临床前和临床数据表明,调节血清素能系统是缓解阿片类药物戒断综合征的一种新型治疗方法:根据临床前研究结果,确定并描述了据报道可介导阿片类戒断症状的血清素受体。然后总结了评估这些受体对阿片类戒断结果的调节作用的现有临床研究:虽然作为血清素受体亚型的激动剂或拮抗剂的药物具有治疗阿片类药物戒断和新生儿阿片类药物戒断综合征的潜力,但大部分证据并不充分。支持性数据主要来自临床前研究,临床疗效的测量结果不尽相同,但症状严重程度的减轻是一致的。血清素能调节为缓解阿片类药物戒断症状提供了一种非阿片类药物途径,这对新生儿尤其有用,因为产后使用阿片类药物会导致神经可塑性发生变化。这些潜在的益处需要更多的研究来阐明其作用机制,并衡量这些药物对人类疾病的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.00
自引率
0.00%
发文量
71
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
期刊最新文献
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases. A focused report on IFN-1 targeted therapies for lupus erythematosus. Mantle cell lymphoma: what clinical progress in the last 5 years? Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1